• Israel prepares for final hostage release as Gazans…
  • Oscar-winning actor Diane Keaton dies at 79
  • Diane Keaton, Oscar-winning actress, dies at 79
  • Diane Keaton, Oscar-winning actor who rose to fame…

Be that!

contact@bethat.ne.com

 

Be That ! Menu   ≡ ╳
  • Home
  • Travel
  • Culture
  • Lifestyle
  • Sport
  • Contact Us
  • Politics Politics
☰

Be that!

Trump on indictments after Comey

admin - Latest News - September 26, 2025
admin
14 views 27 secs 0 Comments



As he departed the White House, President Trump was asked who “the next person on your list in this retribution” will be now that former FBI Director James Comey has been indicted. “It’s not a list,” Trump said, “but I think there’ll be others. I mean, they’re corrupt.”



Source link

TAGS:
PREVIOUS
Sept. 26, 2025, 11:24 AM EDTBy Rob Wile and Steve KopackAnalysts are already warning that U.S. consumers could see higher prices due to new tariffs President Donald Trump plans to impose on drug product imports as soon as next week.But a series of exemptions may blunt the ultimate impact. In a Truth Social post late Thursday, Trump said that any branded or patented pharmaceutical products brought into the U.S. would face a 100% tariff starting Oct. 1.U.S. imports of pharmaceuticals totaled about $213 billion in 2024, a threefold increase from a decade earlier, according to data from the United Nations Comtrade Database.With Asia alone accounting for just over 20% of those imports by value, U.S. consumers could see a “meaningful commercial hit,” Louise Loo, head of Asia economics at Oxford Economics research group, said in a note to clients. Previous studies have shown that U.S. annual spending per capita on prescription drugs is about double the rest of the developed world. In July, Trump announced a plan to “get Americans the best prices in the world for prescription drugs” that involved asking major drugmakers to match low prices they offer elsewhere in the world. However, it is not clear what actions the pharma firms have taken to begin addressing that demand. The pharmaceutical industry is already warning that the new tariffs could derail further drug development while also raising prices. “Every dollar spent on tariffs is a dollar that cannot be invested in American manufacturing or the development of future treatments and cures,” Alex Schriver, senior vice president for PhRMA, the drug industry’s primary lobbying group, said in a statement. “Medicines have historically been exempt from tariffs because they raise costs and could lead to shortages.”Despite those warnings, a significant share of drug products could wind up being exempted from the new import duties. The tariffs do not appear to apply to so-called generic drugs, which account for 9 out of 10 prescriptions filled in the U.S., according to the Food and Drug Administration. The White House did not immediately respond to a request to confirm the exemption for generics, but assuming they will remain tariff-free, the impact to consumers could be more limited than feared. Trump also specified that any drug companies that currently have, or have committed to building, U.S.-based drug-making facilities would be exempted from tariffs. That’s a category that includes numerous major drugmakers. “Many pharmaceutical companies have facilities in the U.S., so it may be relatively easy to superficially expand those facilities to avoid tariffs being applied,” Paul Donovan, chief global economist at UBS Global Wealth Management, wrote in a note to clients. Analysts at JPMorgan agreed: “While there remains very limited details, we note that this will likely lead to a majority of pharma products being excluded from any tariffs” because most major companies have recently increased or have started to increase their U.S. manufacturing facilities.On the White House website, the administration maintains a “running list of new U.S. investment” from private companies. At least 15 pharmaceutical or drug makers are listed with investments ranging from new manufacturing facilities, tens of billions in expanded U.S. production and increased R&D spending. Many of those announcements would appear to meet the requirements laid out by Trump to avoid the new tariff.Two major European drugmakers, Roche and Novartis, said in statements that they expected little to no impact from the newly announced duties. “We are working to ensure that all major Novartis medicines for U.S. patients are manufactured in the U.S.,” Novartis said in a statement. “The announced 100% tariff should not have an impact.” Roche pointed to ongoing factory construction in the U.S., with multiple sites being expanded and upgraded in Kentucky, Indiana, New Jersey and California.Trump has signaled since at least April that drug imports would face tariffs. In anticipation, major drugmakers have indicated they have been stockpiling supplies, analysts said. As a result, consumers are unlikely to feel immediate effects even though the tariffs are set to kick in next week. “We think there may have been significant inventory accumulation this year,” Neil Shearing, group chief economist with Capital Economics, said in a note. This summer, Trump placed a maximum 15% tariff on most pharmaceuticals coming in from the European Union, which accounts for 60% of drugs imported by the U.S. E.U. officials believe that this agreement will shield it from the 100% duties, though they said they could not be certain. “This clear all-inclusive 15% tariff ceiling for E.U. exports represents an insurance policy that no higher tariffs will emerge for European economic operators,” a European Commission spokesperson told NBC News on Friday.Ireland’s deputy prime minister, Simon Harris, who also acts as trade minister, said his country is “studying the impact of this announcement” but added that he believed the 15% cap on pharma tariffs remained in place. Ireland alone accounts for 24% of pharma imports to the U.S.Rob WileRob Wile is a Pulitzer Prize-winning journalist covering breaking business stories for NBCNews.com.Steve KopackSteve Kopack is a senior reporter at NBC News covering business and the economy.
NEXT
Iranian President says Trump's current path will 'set fire' to the Middle East
Related Post
October 2, 2025
Savewith a NBCUniversal ProfileCreate your free profile or log in to save this articleOct. 2, 2025, 6:00 AM EDT / Updated Oct. 2, 2025, 8:41 AM EDTBy Jared PerloSam Altman singing in a toilet. James Bond playing Altman in high-stakes poker. Pikachu storming Normandy’s beaches. Mario jumping from his virtual world into real life.Those are just some of the lifelike videos that are rocketing through the internet a day after OpenAI released Sora, an app at the intersection of social media and artificial intelligence-powered media generation. The app surged to be the most popular app in the iOS App Store’s Photo and Video category within a day of its release.Powered by OpenAI’s upgraded Sora 2 media generation AI model, the app allows users to create high-definition videos from simple text prompts. After it processes one-time video and audio recordings of users’ likenesses, Sora allows users to embed lifelike “cameos” of themselves, their friends and others who give their permission. The app is a recipe made for virality. But many of the videos published within the first day of Sora’s debut have also raised alarm bells from copyright and deepfake experts.Users have so far reported being able to feature video game characters like Lara Croft or Nintendo heavyweights like Mario, Luigi and even Princess Peach in their AI creations. One user inserted Ronald McDonald into a saucy scene from the romantic reality TV show “Love Island.” The Wall Street Journal reported Monday that the app would enable users to feature material protected by copyright unless the copyright holders opted out of having their work appear. However, the report said, blanket opt-outs did not appear to be an option, instead requiring copyright holders to submit examples of offending content.Sora 2 builds on OpenAI’s original Sora model, which was released to the public in December. Unlike the original Sora, Sora 2 now enables users to create videos with matching dialogue and sound effects.AI models ingest large swaths of information in the “training” process as they learn how to respond to users’ queries. That data forms the basis for models’ responses to future user requests. For example, Google’s Veo 3 video generation model was trained on YouTube videos, much to the dismay of some YouTube creators. OpenAI has not clearly indicated which exact data its models draw from, but the appearance of characters under copyright indicates that it used copyright-protected information to design the Sora 2 system. China’s ByteDance and its Seedance video generation model have also attracted recent copyright scrutiny.OpenAI faces legal action over copyright infringement claims, including a high-profile lawsuit featuring authors including Ta-Nehisi Coates and Jodi Picoult and newspapers like The New York Times. OpenAI competitor Anthropic recently agreed to pay $1.5 billion to settle claims from authors who alleged that Anthropic illegally downloaded and used their books to train its AI models. In an interview, Mark McKenna, a law professor and the faculty director of the UCLA Institute for Technology, Law, and Policy, drew a stark line between using copyrighted data as an input to train models and generating outputs that depict copyright-protected information.“If OpenAI is taking an aggressive approach that says they’re going to allow outputs of your copyright-protected material unless you opt out, that strikes me as not likely to work. That’s not how copyright law works. You don’t have to opt out of somebody else’s rules,” McKenna said.“The early indications show that training AI models on legitimately acquired copyright material can be considered fair use. There’s a very different question about the outputs of these systems,” he continued. “Outputting visual material is a harder copyright question than just the training of models.”As McKenna sees it, that approach is a calculated risk. “The opt-out is clearly a ‘move fast and break things’ mindset,” he said. “And the aggressive response by some of the studios is ‘No, we’re not going to go along with that.’”Disney, Warner Bros. and Sony Music Entertainment did not reply to requests for comment.In addition to copyright issues, some observers were unsettled by one of the most popular first-day creations, which depicted OpenAI CEO Sam Altman stealing valuable computer components from Target — illustrating the ease with which Sora 2 can create content depicting real people committing crimes they had not actually committed. Sora 2’s high-quality outputs arrive as some have expressed concerns about illicit or harmful creations, from worries about gory scenes and child safety to the model’s role in spreading deepfakes. OpenAI includes techniques to indicate Sora 2’s creations are AI-generated as concerns grow about the ever-blurrier line between reality and computer-generated content.Sora 2 will include moving watermarks on all videos on the Sora app or downloaded from sora.com, while invisible metadata will indicate Sora-generated videos are created by AI systems.However, the metadata can be easily removed. OpenAI’s own documentation says the metadata approach “is not a silver bullet to address issues of provenance. It can easily be removed either accidentally or intentionally,” like when users upload images to social media websites.Siwei Lyu, a professor of computer science and the director of the University of Buffalo’s Media Forensic Lab and Center for Information Integrity, agreed that multiple layers of authentication were key to prove content’s origin from Sora. “OpenAI claimed they have other responsible use measures, such as the inclusion of visible and invisible watermarks, and tracing tools for Sora-made images and audio. These complement the metadata and provide an additional layer of protection,” Lyu said.“However, their effectiveness requires additional testing. The invisible watermark and tracing tools can only be tested internally, so it is hard to judge how well they work at this point,” he added.OpenAI addressed those limitations in its technical safety report, writing that “we will continue to improve the provenance ecosystem to help bring more transparency to content created from our tools.” OpenAI did not immediately reply to a request for comment.Though the Sora app is available for download, access to Sora’s services remains invitation-only as OpenAI gradually increases access. Jared PerloJared Perlo is a writer and reporter at NBC News covering AI. He is currently supported by the Tarbell Center for AI Journalism.
September 22, 2025
Officials react to recognition of Palestinian state
October 9, 2025
Letitia James, a Trump opponent, is indicted by a grand jury on bank fraud charge
October 8, 2025
Texas National Guard Troops Arrive Outside Chicago
Comments are closed.
Scroll To Top
  • Home
  • Travel
  • Culture
  • Lifestyle
  • Sport
  • Contact Us
  • Politics
© Copyright 2025 - Be That ! . All Rights Reserved